|
02 Aug 2018 |
Medicenna Provides Development Update on MDNA109 IL-2 Superkine Program
|
|
02 Aug 2018 |
Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study
|
|
02 Aug 2018 |
Evolus Announces Early Resubmission to the FDA of its Biologics License Application for DWP-450
|
|
31 Jul 2018 |
Aegerion’s Myalepta Approved in Europe : the First Treatment Indicated for Patients with Ultra-Rare Disease, Lipodystrophy
|
|
27 Jul 2018 |
Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA™ (Pegfilgrastim Biosimilar Candidate)
|
|
27 Jul 2018 |
Accord Healthcare’s (Intas) Pelgraz® (pegfilgrastim) Given Green Light by CHMP
|
|
24 Jul 2018 |
Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease
|
|
21 Jul 2018 |
U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)
|
|
10 Jul 2018 |
Filament BioSolutions Announces Collaboration with Ajinomoto for the Development of FB-2710 for Radiation-Induced Oral Mucositis
|
|
10 Jul 2018 |
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
|
|
06 Jul 2018 |
Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki
|
|
04 Jul 2018 |
FDA Approves XEOMIN® (incobotulinumtoxinA) for Adult Patients with Sialorrhea
|
|
03 Jul 2018 |
CHMP recommends EU marketing authorization for Veyvondi® [vonicog alfa, recombinant von Willebrand factor] for adults with von willebrand disease
|
|
02 Jul 2018 |
VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants
|
|
01 Jul 2018 |
Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII
|
|
29 Jun 2018 |
Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint
|
|
29 Jun 2018 |
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
|
|
28 Jun 2018 |
Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3
|
|
27 Jun 2018 |
Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis
|
|
27 Jun 2018 |
Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris
|
|
26 Jun 2018 |
Cerenis Therapeutics: First results of TARGET PHASE II study demonstrate the ability of CER-001, an HDL mimetic, to target tumor in patients with esophageal cancer
|
|
26 Jun 2018 |
Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen
|
|
26 Jun 2018 |
Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN
|
|
25 Jun 2018 |
Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer
|
|
24 Jun 2018 |
Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
|
